WO2011018801A3 - Solid oral dosage form of ziprasidone - Google Patents
Solid oral dosage form of ziprasidone Download PDFInfo
- Publication number
- WO2011018801A3 WO2011018801A3 PCT/IN2010/000537 IN2010000537W WO2011018801A3 WO 2011018801 A3 WO2011018801 A3 WO 2011018801A3 IN 2010000537 W IN2010000537 W IN 2010000537W WO 2011018801 A3 WO2011018801 A3 WO 2011018801A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ziprasidone
- dosage form
- oral dosage
- solid oral
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A solid oral dosage form comprising ziprasidone or its pharmaceutically acceptable salt and cationic ion exchange resin and the process of its preparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1863MU2009 | 2009-08-12 | ||
IN1863/MUM/2009 | 2009-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011018801A2 WO2011018801A2 (en) | 2011-02-17 |
WO2011018801A3 true WO2011018801A3 (en) | 2011-04-07 |
Family
ID=43586593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2010/000537 WO2011018801A2 (en) | 2009-08-12 | 2010-08-12 | Solid oral dosage form of ziprasidone |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011018801A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130108701A1 (en) | 2010-05-25 | 2013-05-02 | Krishna Murthy Bhavanasi | Solid Dosage Forms of Antipsychotics |
KR101660609B1 (en) * | 2012-02-06 | 2016-09-27 | 도요타지도샤가부시키가이샤 | Sulfide solid electrolyte material, battery, and method for producing sulfide solid electrolyte material |
ES2441468B1 (en) * | 2012-08-03 | 2014-11-13 | Laboratorios Rubió, S.A. | SOLID PHARMACEUTICAL COMPOSITION OF CATIÓNIC EXCHANGE RESIN. |
CN103417541A (en) * | 2013-08-22 | 2013-12-04 | 万特制药(海南)有限公司 | Drug resin salt containing Ziprasidone and salt thereof and preparation method of drug resin salt |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0830864A1 (en) * | 1996-09-23 | 1998-03-25 | Eli Lilly And Company | Combination therapy for treatment of psychoses |
WO2005065660A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Ziprasidone formulations |
-
2010
- 2010-08-12 WO PCT/IN2010/000537 patent/WO2011018801A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0830864A1 (en) * | 1996-09-23 | 1998-03-25 | Eli Lilly And Company | Combination therapy for treatment of psychoses |
WO2005065660A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Ziprasidone formulations |
Also Published As
Publication number | Publication date |
---|---|
WO2011018801A2 (en) | 2011-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL206500A0 (en) | Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
WO2009084024A3 (en) | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof | |
IL245050A0 (en) | Optimized fc variants, pharmaceutical compositions and medicaments comprising the same, and methods for their production | |
IL250439A0 (en) | Use of fingolimod, or a phosphate derivative thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of multiple sclerosis | |
EP2455095A4 (en) | Prophylactic, ameliorating or therapeutic agent for oral diseases | |
EP2450046A4 (en) | A medicinal composition for the treatment of bronchitis and preparation thereof | |
WO2010117738A3 (en) | Solid state forms of sitagliptin salts | |
IL193340A0 (en) | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
EP2273975B8 (en) | Pharmaceutical solutions, process of preparation and therapeutic uses | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2011012322A3 (en) | Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms | |
EP2086945A4 (en) | Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof | |
ZA201201349B (en) | Dihydropteridinone derivatives, preparation process amd pharmaceutical use thereof | |
IL203051A (en) | Use of alpha-ketoglutarate for the preparation of medicaments | |
EP1968943A4 (en) | An improved process for the preparation of montelukast and its pharmaceutically acceptable salts | |
EP2624815B8 (en) | Oral vaccine fast-dissolving dosage form using starch | |
WO2011076212A3 (en) | Processes for the manufacture of a pharmaceutically active agent | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
WO2010148314A3 (en) | Preparation of esomeprazole and its pharmaceutically acceptable salts | |
WO2011018801A3 (en) | Solid oral dosage form of ziprasidone | |
SI2536396T1 (en) | Process for the preparation of oral solid dosage forms comprising valsartan | |
PL2291374T3 (en) | Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity | |
HUP0700756A2 (en) | Process for the preparation of pharmaceutical intermediers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10808049 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10808049 Country of ref document: EP Kind code of ref document: A2 |